Literature DB >> 23674329

Insight into the toxic effects of cis-dichloridoplatinum(II) complexes containing 7-azaindole halogeno derivatives in tumor cells.

Tereza Muchova1, Jitka Pracharova, Pavel Starha, Radana Olivova, Oldrich Vrana, Barbora Benesova, Jana Kasparkova, Zdenek Travnicek, Viktor Brabec.   

Abstract

The cisplatin analogues cis-[PtCl2(3ClHaza)2] (1) and cis-[PtCl2(3IHaza)2] (2) (3ClHaza and 3IHaza are 3-chloro-7-azaindole and 3-iodo-7-azaindole, respectively) are quite toxic to ovarian tumor cells, with moderately better IC50 values than for cisplatin in the cisplatin-sensitive cell line A2780. We investigated potential factors which might be involved in the mechanism underlying the cytotoxic effects of 1 and 2 and compared these factors with those involved in the mechanism underlying the effects of conventional cisplatin. Our data indicate that the higher cytotoxicity of 1 and 2 originates mainly from their efficient cellular accumulation, different effects at the level of cell cycle regulation, and reduced propensity for DNA adduct repair. Studies of their reactivity toward cellular components reveal efficient binding to DNA, which is typically required for an active platinum drug. Further results suggest that 1 and 2 are capable of circumventing resistance to cisplatin induced by alterations in cellular accumulation and DNA repair. Hence, the latter two factors appear to be responsible for differences in the toxicity of 1 or 2, and cisplatin in tumor cells. The results of this work reinforce the idea that direct analogues of conventional cisplatin-containing halogeno-substituted 7-azaindoles offer much promise for the design of novel therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23674329     DOI: 10.1007/s00775-013-1003-7

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  40 in total

1.  Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine)platinum(II).

Authors:  A Eastman
Journal:  Biochemistry       Date:  1983-08-02       Impact factor: 3.162

Review 2.  Cellular processing of platinum anticancer drugs.

Authors:  Dong Wang; Stephen J Lippard
Journal:  Nat Rev Drug Discov       Date:  2005-04       Impact factor: 84.694

Review 3.  Resistance to cisplatin.

Authors:  S Akiyama; Z S Chen; T Sumizawa; T Furukawa
Journal:  Anticancer Drug Des       Date:  1999-04

Review 4.  The role of sulfur in platinum anticancer chemotherapy.

Authors:  Xiaoyong Wang And; Zijian Guo
Journal:  Anticancer Agents Med Chem       Date:  2007-01       Impact factor: 2.505

5.  Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations.

Authors:  Tito Fojo; Nick Farrell; Waldo Ortuzar; Hideyuki Tanimura; John Weinstein; Timothy G Myers
Journal:  Crit Rev Oncol Hematol       Date:  2005-01       Impact factor: 6.312

6.  Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.

Authors:  J T Reardon; A Vaisman; S G Chaney; A Sancar
Journal:  Cancer Res       Date:  1999-08-15       Impact factor: 12.701

7.  A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.

Authors:  L R Kelland; C F Barnard; K J Mellish; M Jones; P M Goddard; M Valenti; A Bryant; B A Murrer; K R Harrap
Journal:  Cancer Res       Date:  1994-11-01       Impact factor: 12.701

8.  Positive correlation between cellular glutathione and acquired cisplatin resistance in human ovarian cancer cells.

Authors:  G Chen; K J Hutter; W J Zeller
Journal:  Cell Biol Toxicol       Date:  1995-10       Impact factor: 6.691

Review 9.  The resurgence of platinum-based cancer chemotherapy.

Authors:  Lloyd Kelland
Journal:  Nat Rev Cancer       Date:  2007-07-12       Impact factor: 60.716

10.  Differences in the cellular response and signaling pathways between cisplatin and monodentate organometallic Ru(II) antitumor complexes containing a terphenyl ligand.

Authors:  Anna Kisova; Lenka Zerzankova; Abraha Habtemariam; Peter J Sadler; Viktor Brabec; Jana Kasparkova
Journal:  Mol Pharm       Date:  2011-04-19       Impact factor: 4.939

View more
  6 in total

1.  Potentiating effect of UVA irradiation on anticancer activity of Carboplatin derivatives involving 7-azaindoles.

Authors:  Pavel Štarha; Zdeněk Trávníček; Zdeněk Dvořák; Tereza Radošová-Muchová; Jitka Prachařová; Ján Vančo; Jana Kašpárková
Journal:  PLoS One       Date:  2015-04-15       Impact factor: 3.240

2.  Pharmacological and molecular effects of platinum(II) complexes involving 7-azaindole derivatives.

Authors:  Pavel Starha; Jan Hošek; Ján Vančo; Zdeněk Dvořák; Pavel Suchý; Igor Popa; Gabriela Pražanová; Zdeněk Trávníček
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

3.  Platinum(II) Iodido Complexes of 7-Azaindoles with Significant Antiproliferative Effects: An Old Story Revisited with Unexpected Outcomes.

Authors:  Pavel Štarha; Ján Vančo; Zdeněk Trávníček; Jan Hošek; Jarmila Klusáková; Zdeněk Dvořák
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

4.  In Vitro Antitumor Active Gold(I) Triphenylphosphane Complexes Containing 7-Azaindoles.

Authors:  Pavel Štarha; Zdeněk Trávníček; Bohuslav Drahoš; Zdeněk Dvořák
Journal:  Int J Mol Sci       Date:  2016-12-11       Impact factor: 5.923

5.  Novel cis-Pt(II) Complexes with Alkylpyrazole Ligands: Synthesis, Characterization, and Unusual Mode of Anticancer Action.

Authors:  Jana Kasparkova; Hana Kostrhunova; Vojtech Novohradsky; Аlexey A Logvinov; Viktor V Temnov; Nataliya E Borisova; Tatiana A Podrugina; Lenka Markova; Pavel Starha; Alexey A Nazarov; Viktor Brabec
Journal:  Bioinorg Chem Appl       Date:  2022-03-02       Impact factor: 7.778

6.  Highly and Broad-Spectrum In Vitro Antitumor Active cis-Dichloridoplatinum(II) Complexes with 7-Azaindoles.

Authors:  Pavel Štarha; Zdeněk Dvořák; Zdeněk Trávníček
Journal:  PLoS One       Date:  2015-08-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.